FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118111915> ?p ?o ?g. }

• W3118111915 endingPage "4734" @default.
• W3118111915 startingPage "4722" @default.
• W3118111915 abstract "// Michael Rees 1 , 2 , Chris Smith 1 , Peter Barrett-Lee 2 and Steve Hiscox 1 1 Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK 2 Velindre Cancer Centre, Cardiff, UK Correspondence to: Michael Rees, email: michael.rees2@wales.nhs.uk Steve Hiscox, email: hiscoxse1@Cardiff.ac.uk Keywords: breast cancer; PELP-1; ER+; invasion Received: August 25, 2020     Accepted: November 20, 2020     Published: December 22, 2020 Copyright: © 2020 Rees et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Introduction: Endocrine therapy has played an important role in the management of ER positive breast cancer over recent decades. Despite this, not all patients respond equally to endocrine intervention, which can lead to resistance, associated disease relapse and progression. Previous reports suggest that endocrine agents themselves may induce an invasive phenotype in ER positive breast cancers with low/aberrant expression of E-cadherin. Here we investigate this phenomenon further and provide data supporting a role for the ER co-receptor, PELP-1, in mediating an adverse response to endocrine agents. Materials and Methods: The effects of tamoxifen, fulvestrant and estrogen withdrawal (as a model for aromatase inhibitor therapy) on the invasive and migratory capacity of endocrine-sensitive MCF-7 and T47D cells, in the presence or absence of functional E-cadherin and/or PELP-1 (using siRNA knockdown), was assessed via Matrigel invasion and Boyden chamber migration assays. The effects of these endocrine therapies alongside E-cadherin/PELP-1 modulation on cell proliferation were further assessed by MTT assay. Western blotting using phospho-specific antibodies was performed to investigate signalling pathway changes associated with endocrine-induced changes in invasion and migration. Results: Both tamoxifen and fulvestrant induced a pro-invasive and pro-migratory phenotype in ER positive breast cancer cells displaying a high basal expression of PELP-1, which was augmented in the context of poor cell-cell contact. This process occurred in a Src-dependent manner with Src inhibition reversing endocrine induced invasion/migration. While this adverse response was observed using both tamoxifen and fulvestrant therapy, it was not observed under conditions of estrogen withdrawal. Conclusions: Our data confirms previous reports that anti-estrogens induce an adverse cell phenotype in ER+ breast cancer, particularly in the absence of homotypic cell contact. These results implicate E-cadherin and PELP-1 as potential biomarkers when deciding upon optimum adjuvant endocrine therapy, whereby tumours with high PELP-1/low E-cadherin expression may benefit from estrogen withdrawal therapy via aromatase inhibition, as opposed to ER modulation/antagonism." @default.
• W3118111915 created "2021-01-05" @default.
• W3118111915 creator A5005543736 @default.
• W3118111915 creator A5007328952 @default.
• W3118111915 creator A5028884075 @default.
• W3118111915 creator A5079959615 @default.
• W3118111915 date "2020-12-22" @default.
• W3118111915 modified "2023-10-05" @default.
• W3118111915 title "PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer" @default.
• W3118111915 cites W1516914181 @default.
• W3118111915 cites W1522060570 @default.
• W3118111915 cites W1576319682 @default.
• W3118111915 cites W1578523240 @default.
• W3118111915 cites W1662062786 @default.
• W3118111915 cites W1961026612 @default.
• W3118111915 cites W1970392892 @default.
• W3118111915 cites W1974468585 @default.
• W3118111915 cites W1976999762 @default.
• W3118111915 cites W1982462460 @default.
• W3118111915 cites W1985453548 @default.
• W3118111915 cites W1991371485 @default.
• W3118111915 cites W1995573963 @default.
• W3118111915 cites W2002514277 @default.
• W3118111915 cites W2010296464 @default.
• W3118111915 cites W2025827059 @default.
• W3118111915 cites W2030781089 @default.
• W3118111915 cites W2046748396 @default.
• W3118111915 cites W2053567347 @default.
• W3118111915 cites W2065956281 @default.
• W3118111915 cites W2071443411 @default.
• W3118111915 cites W2072613049 @default.
• W3118111915 cites W2087305746 @default.
• W3118111915 cites W2090631044 @default.
• W3118111915 cites W2092624579 @default.
• W3118111915 cites W2109462974 @default.
• W3118111915 cites W2115387040 @default.
• W3118111915 cites W2118728607 @default.
• W3118111915 cites W2129958055 @default.
• W3118111915 cites W2135247786 @default.
• W3118111915 cites W2147549133 @default.
• W3118111915 cites W2148570851 @default.
• W3118111915 cites W2150026213 @default.
• W3118111915 cites W2154478723 @default.
• W3118111915 cites W2156288839 @default.
• W3118111915 cites W2156345809 @default.
• W3118111915 cites W2165999332 @default.
• W3118111915 cites W2290950904 @default.
• W3118111915 cites W2300860717 @default.
• W3118111915 cites W55933262 @default.
• W3118111915 doi "https://doi.org/10.18632/oncotarget.27846" @default.
• W3118111915 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7771710" @default.
• W3118111915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33473257" @default.
• W3118111915 hasPublicationYear "2020" @default.
• W3118111915 type Work @default.
• W3118111915 sameAs 3118111915 @default.
• W3118111915 citedByCount "1" @default.
• W3118111915 countsByYear W31181119152022 @default.
• W3118111915 crossrefType "journal-article" @default.
• W3118111915 hasAuthorship W3118111915A5005543736 @default.
• W3118111915 hasAuthorship W3118111915A5007328952 @default.
• W3118111915 hasAuthorship W3118111915A5028884075 @default.
• W3118111915 hasAuthorship W3118111915A5079959615 @default.
• W3118111915 hasBestOaLocation W31181119151 @default.
• W3118111915 hasConcept C121608353 @default.
• W3118111915 hasConcept C126322002 @default.
• W3118111915 hasConcept C143998085 @default.
• W3118111915 hasConcept C197934379 @default.
• W3118111915 hasConcept C2776166826 @default.
• W3118111915 hasConcept C2777176818 @default.
• W3118111915 hasConcept C2780482068 @default.
• W3118111915 hasConcept C46699223 @default.
• W3118111915 hasConcept C530470458 @default.
• W3118111915 hasConcept C71315377 @default.
• W3118111915 hasConcept C71924100 @default.
• W3118111915 hasConcept C84606932 @default.
• W3118111915 hasConceptScore W3118111915C121608353 @default.
• W3118111915 hasConceptScore W3118111915C126322002 @default.
• W3118111915 hasConceptScore W3118111915C143998085 @default.
• W3118111915 hasConceptScore W3118111915C197934379 @default.
• W3118111915 hasConceptScore W3118111915C2776166826 @default.
• W3118111915 hasConceptScore W3118111915C2777176818 @default.
• W3118111915 hasConceptScore W3118111915C2780482068 @default.
• W3118111915 hasConceptScore W3118111915C46699223 @default.
• W3118111915 hasConceptScore W3118111915C530470458 @default.
• W3118111915 hasConceptScore W3118111915C71315377 @default.
• W3118111915 hasConceptScore W3118111915C71924100 @default.
• W3118111915 hasConceptScore W3118111915C84606932 @default.
• W3118111915 hasIssue "51" @default.
• W3118111915 hasLocation W31181119151 @default.
• W3118111915 hasLocation W31181119152 @default.
• W3118111915 hasLocation W31181119153 @default.
• W3118111915 hasLocation W31181119154 @default.
• W3118111915 hasOpenAccess W3118111915 @default.
• W3118111915 hasPrimaryLocation W31181119151 @default.
• W3118111915 hasRelatedWork W159153186 @default.
• W3118111915 hasRelatedWork W160269717 @default.
• W3118111915 hasRelatedWork W1982896522 @default.
• W3118111915 hasRelatedWork W1983499475 @default.

• next